Details

Autor(en) / Beteiligte

• Li, Xin
• Zhou, Jianbo
• Wang, Xue
• Li, Chunxi
• Ma, Zifan
• Wan, Qiaoling
• Peng, Fu

Titel

New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis

Ist Teil von

• Biomedicine & pharmacotherapy, 2023-07, Vol.163, p.114806-114806, Article 114806

Ort / Verlag

France: Elsevier Masson SAS

Erscheinungsjahr

2023

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In 1971, Folkman proposed that tumors could be limited to very small sizes by blocking angiogenesis. Angiogenesis is the generation of new blood vessels from pre-existing vessels, considered to be one of the important processes in tumor growth and metastasis. Angiogenesis is a complex process regulated by various factors and involves many secreted factors and signaling pathways. Angiogenesis is important in the transport of oxygen and nutrients to the tumor during tumor development. Therefore, inhibition of angiogenesis has become an important strategy in the clinical management of many solid tumors. Combination therapies of angiogenesis inhibitors with radiotherapy and chemotherapy are often used in clinical practice. In this article, we will review common targets against angiogenesis, the most common and up-to-date anti-angiogenic drugs and clinical treatments in recent years, including active ingredients from chemical and herbal medicines. [Display omitted] •Angiogenesis, the generation of new blood vessels from those already present, is an important process in tumor development.•Angiogenic targets are focused on pro-angiogenic factors, angiogenic chemokines, and angiogenesis-associated factors.•Common clinical angiogenesis-targeting compounds and herbal and food extracts with anti-angiogenic potential are summarized.•This article describes advanced angiogenesis treatment technologies including combination therapy, gene therapy, nano-delivery systems, and vaccines.